Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. The company is headquartered in Boston, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-01-02. The firm is engaged in developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform harnesses the patient’s intrinsic immune repertoire to fully exploit its potential to fight cancer and restore health while avoiding the deleterious side effects of broad immune activation. The Company’s lead product candidate from the CUE-100 series, CUE-101, is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers. Its second drug product candidate, CUE-102, targets Wilms’ Tumor 1 protein (WT-1), an oncofetal antigen. The company is also developing CUE-103 and its Neo-STAT and RDI-STAT programs outside of oncology.